VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2021 | Updates on Cami-T for Hodgkin lymphoma

Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses the latest updates on camidanlumab tesirine (Cami-T), a CD25-targeting antibody-drug conjugate, for the treatment of Hodgkin lymphoma. Prof. Ansell reports that Cami-T has demonstrated sustained high response rates in patients with Hodgkin lymphoma, especially in those who failed on standard treatments and transplant. Currently, Cami-T is being administered as a monotherapy after chemotherapy and PD-1 blockade failure, but in the future it is expected that Cami-T may be used in combinatorial approaches. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter